» Articles » PMID: 1067618

Control of the Amplification Convertase of Complement by the Plasma Protein Beta1H

Overview
Specialty Science
Date 1976 Sep 1
PMID 1067618
Citations 241
Authors
Affiliations
Soon will be listed here.
Abstract

An inhibitory activity for an erythrocyte in termediate bearing the properdin (P)-stabilized amplification C3 convertase, PC3bBb, was recognized in whole normal human serum and separated from C3b inactivator by its distinct physicochemical and functional characteristics. The inhibitory activity was found to reside in a protein that was purified to homogeneity and elicited a monospecific antibody in a rabbit. This protein was identified as beta1H and found to have a serum concentration of 516 +/- 89 mug/ml (mean +/- 1 SD). beta1H produced a dose related, first-order loss of convertase function and release of 125I-Bb from the P-stabilized intermediate, indicating a mechanism of action by decay-dissociation of Bb from the complex, PC3bBb. beta1H exhibited only a limited capacity to accelerate decay of C3bBb sites stabilized with C3 nephritic factor or to release 125I-Bb from such sites. Amplification of C3 cleavage by C3bBb may well determine whether initial complement activation by the classical or alternative activating sequence is beneficial or detrimental to the host. Regulation of this amplifying function is now recognized to occur at at least three steps: intrinsic decay which reflects the inherent lability of the C3bBb convertase; extrinsic decay-dissociation of Bb which is mediated by the effect of beta1H; and inactivation of exposed C3b by C3b inactivator. The stabilization of C3bBb by activated properdin minimizes intrinsic decay and protects C3b in the bimolecular complex from C3b inactivator. beta1H restores control of the system by decay-dissociation of the bimolecular complex, therby exposing C3b to C3b inactivator whose irreversible action prevents regeneration of the convertase at that site.

Citing Articles

Factor B as a therapeutic target for the treatment of complement-mediated diseases.

Kavanagh D, Barratt J, Schubart A, Webb N, Meier M, Fakhouri F Front Immunol. 2025; 16:1537974.

PMID: 40028332 PMC: 11868072. DOI: 10.3389/fimmu.2025.1537974.


Non-canonical roles of CFH in retinal pigment epithelial cells revealed by dysfunctional rare CFH variants.

Brink S, ten Brink S, Koolen L, Klaver C, Bakker R, den Hollander A Stem Cell Reports. 2025; 20(1):102385.

PMID: 39753135 PMC: 11784488. DOI: 10.1016/j.stemcr.2024.11.015.


A surface lipoprotein on binds complement factor I to promote immune evasion.

Nguyen Q, Lai C, Norris M, Ng D, Shah M, Lai C bioRxiv. 2024; .

PMID: 39484374 PMC: 11526892. DOI: 10.1101/2024.10.21.619360.


Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity.

Tschongov T, Konwar S, Busch A, Sievert C, Hartmann A, Noris M Front Immunol. 2024; 15:1383123.

PMID: 38799460 PMC: 11117068. DOI: 10.3389/fimmu.2024.1383123.


Protective role of complement factor H against the development of preeclampsia.

Yasmin H, Agostinis C, Toffoli M, Roy T, Pegoraro S, Balduit A Front Immunol. 2024; 15:1351898.

PMID: 38464530 PMC: 10920295. DOI: 10.3389/fimmu.2024.1351898.


References
1.
Nilsson U, MUELLER-EBERHARD H . ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med. 1965; 122:277-98. PMC: 2138056. DOI: 10.1084/jem.122.2.277. View

2.
MUELLER-EBERHARD H, Lepow I . C'1 ESTERASE EFFECT ON ACTIVITY AND PHYSICOCHEMICAL PROPERTIES OF THE FOURTH COMPONENT OF COMPLEMENT. J Exp Med. 1965; 121:819-33. PMC: 2137997. DOI: 10.1084/jem.121.5.819. View

3.
Lepow I, Naff G, Todd E, Pensky J, Hinz C . Chromatographic resolution of the first component of human complement into three activities. J Exp Med. 1963; 117:983-1008. PMC: 2137589. DOI: 10.1084/jem.117.6.983. View

4.
PILLEMER L, Blum L, Lepow I, Ross O, Todd E, Wardlaw A . The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954; 120(3112):279-85. DOI: 10.1126/science.120.3112.279. View

5.
Ruddy S, Austen K . C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol. 1971; 107(3):742-50. View